FindTrial
Sign In

Galectin-3 and oral submucous fibrosis

Evaluation of immunoexpression of galectin-3 in oral submucous fibrosis and healthy oral mucosa.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029928
Enrollment
40
Registered
2020-12-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx Health Condition 2: K135- Oral submucous fibrosis

Interventions

Intervention1: tissue biopsy and special staining: H & E stain and Galectin-3 immunohistochemistry on tissue sections, 2 months Control Intervention1: Nil: Nil Control Intervention2: Nil: Nil Control

Sponsors

Dr Hetvi Sheth
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed cases of OSMF with or without malignant transformation.

Exclusion criteria

Exclusion criteria: 1. Patient who has undergone any kind of invasive treatment for OSMF before. 2. Patient with any systemic and infectious disease. 3. The patient who is not willing to participate in the study.

Design outcomes

Primary

MeasureTime frame
Role of Galectin-3 in pathogenesis of Oral submucous fibrosisTimepoint: 8 weeks—

Secondary

MeasureTime frame
Role of Galectin-3 in pathogenesis of Oral submucous fibrosisTimepoint: 8 weeks—

Countries

India

Contacts

Public ContactDr Arpan Shah

Manubhai Patel Dental College Hospital and ORI

drarpan_shah@rediffmail.com08141258139

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026